The CEO of clinical stage pharma BeyondSpring Inc. – which has operations in China and the US – expects its lead investigative asset plinabulin to get quicker approval under China's new drug approval approach.
That view was reinforced on Dec. 4 by news that authorities there designated BeyondSpring's novel small molecule – currently in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?